Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,583 INR | -0.02% | +0.71% | +19.69% |
17/06 | Lupin Appoints CEO for Subsidiary Lupin Manufacturing Solutions | MT |
14/06 | Lupin Gets Zero Observations from US FDA After Nagpur, India Unit Inspection | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.63 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.76 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.69% | 8.64B | - | ||
+54.91% | 811B | C+ | ||
+43.62% | 640B | B | ||
-7.16% | 353B | C+ | ||
+17.85% | 333B | B- | ||
+8.62% | 302B | C+ | ||
+16.30% | 246B | B+ | ||
+2.41% | 225B | A+ | ||
+12.47% | 218B | B- | ||
+8.57% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LUPIN Stock
- LUPIN Stock
- Ratings Lupin Limited